Biogen Idec (BIIB) is a biotechnology company with two major products, Avonex (an interferon), which treats multiple sclerosis, and Rituxan (a monoclonal antibody), which treats non-Hodgkin’s lymphoma. Near-term growth is likely to come from the drug Tysabri, another monoclonal antibody meant for treatment of multiple sclerosis. Tysabri was withdrawn from the market after several clinical [...]
More on this topic
(What's this?)
Biogen wants Facet
(Fusion Investing and Analysis, 9/4/09)
FDA, Clinical Trial Updates: BIIB, SLXP, CTIC, PFE, Roche
(Bullish Bankers, 5/26/09)
Seth Klarman Sells Facet Biotech (FACT) Shares & His Entire Horizon Lines (HRZ) Position
(market folly, 9/10/09)
